Purchase this article with an account.
M. E. Pons, R. Aguilar, M. Hoonjan, C. A. Garcia; Intraocular Pressure Profile of Intravitreal Bevacizumab Injections in Wet Amd and Glaucoma Patients. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1898.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the post-injection intraocular pressure (IOP) profile in patients requiring an intravitreal bevacizumab injection, with and without glaucoma.
Charts of patients with various diagnosis requiring bevacizumab injections from Jan 1, 2008 to November 1, 2008 were examined retrospectively. Patients identified meeting the inclusion criteria were divided in two groups: with and without glaucoma. They had bevacizumab intravitreal injections by a single physician using the same technique. IOP was measured immediately before and after the injection.
Forty four patients were included. In the glaucoma group, 4 patients had a diagnosis of primary open angle glaucoma and exudative macular degeneration and 3 had neovascular glaucoma. The group without glaucoma included 37 patients treated for exudative macular degeneration. The mean IOP post injection was higher in the glaucoma group when compared to the non-glaucoma group (r=43.62, r=31.95; p=0.001, respectively). The IOP increased 130% in the non-glaucoma group and 140% from baseline in the glaucoma group. There was no significant difference in the percentage of IOP increase between the two groups (p=0.72).
Patients with glaucoma showed higher IOP after bevacizumab injection. However, bevacizumab injection produced the same percentage of IOP increase in patients with and without glaucoma.
This PDF is available to Subscribers Only